جستجوی مقالات مرتبط با کلیدواژه "hepg-2" در نشریات گروه "پزشکی"

Hepatocellular carcinoma (HCC) is one of the most fatal cancers, so, proposing new anticancer agents is highly valuable. Production of reactive oxygen species (ROS) is increased in majority of cancers. Increase in ROS leads to cell damage and death. Aminoguanidine (AG) (pimagedine) is one of the compounds that can produce ROS at high concentrations. The present study was conducted to evaluate the effect of aminoguanidine on HepG-2 cell survival and ROS production. HepG-2 cell were cultured in complete culture medium. To evaluate the viability, MTT assay was done through spectrophotometry. ROS production was measured by fluorimetry using DCFDA dye, and photographs were taken using fluorescent microscope. MTT assay showed 50% decrease in metabolic activity in the cells treated with aminoguanidine 40 mM (54.8±5.2) after 24 hours. Additionally, the results of ROS measurements showed that ROS formation increased by the elevation of aminoguanidine at concentrations above 40 mM. Aminoguanidine could increase ROS production and decrease the cell viability at 40 mM and higher concentrations, therefore, it can induce other cellular pathways including oxidative and nitrosative stress, apoptosis, and necrosis in HepG-2 cells. Interestingly, AG showed antioxidant potentials in concentrations lower than 40 mM and further investigations are needed to clarify this pattern.

 Hepatocellular carcinoma (HCC) is a most common liver malignancy and TLR9 (Toll-like receptor) is essential for CpG DNA-induced immune responses. The aim of this study was to assess the anti-metastatic effects of combined administration of silibinin and CpG-ODN2006 on human hepatocellular carcinoma HepG-2 cell line model.    Inhibitory effects of various different concentrations of silibinin and CpG-ODN2006 on HepG-2 cells growth and detection of best dosages for simultaneously treatment were assessed by MTT method. Expression of MMP2 and TLR9 genes was analyzed by real- time PCR. Gelatin zymography was used to determine the activity of MMP2.  Inhibitory effects of determined concentrations of silibinin (100 μM) and CpG-ODN2006 (100 nM) on HepG-2 cells growth was significant (p<0.05). Real-Time PCR showed no significant differences between Ct of the genes expression analyses.   Collectively, the data in this study supports the idea of combined silibinin-CpG administration in hepatic cancer customized therapeutic modalities. However, more investigations to assess immunomodulatory effects and safety analyses would be very informative steps in advance of randomized clinical trials.